[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital of Philadelphia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":646},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,77,0,25,[9,43,69,94,122,150,182,211,233,257,277,301,329,345,368,390,423,444,461,494,521,549,571,593,621],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":12,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100560864","refer2quit-evaluating-a-proactive-tailored-population-health-approach-for-tobacco-treatment-for-household-smokers-through-a-pediatric-care-network-100560864",false,"NCT06582693","Refer2Quit: Evaluating a Proactive, Tailored, Population Health Approach for Tobacco Treatment for Household Smokers Through a Pediatric Care Network","Adult Intervention Subject Inclusion Criteria\n\n* Males or females ages ≥18 years in age\n* Self-identify as a current combustible tobacco user\n* Have a valid cell phone number\n\nChild Intervention Subject Inclusion Criteria\n\n* Must be a CHOP patient\n\nAdult Intervention Subject Exclusion Criteria\n\n* \\\u003C18 years in age.\n* Indicates no combustible tobacco smoking\n\nChild Intervention Subject Exclusion Criteria\n\n* Not a CHOP patient\n\nAdult Control Subject Inclusion Criteria\n\n* Males or females ages ≥18 years in age\n* Self-identify as a current combustible tobacco user\n* Have a valid cell phone number\n\nChild Control Subject Inclusion Criteria\n\n* Must be a CHOP patient\n\nAdult Control Subject Exclusion Criteria\n\n* \\\u003C18 years in age.\n* Indicates no combustible tobacco smoking\n\nChild Control Subject Exclusion Criteria\n\n* Not a CHOP patient","ALL","18 Years",{"count":19,"type":20},3200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to compare the reach and effectiveness of the Refer2Quit intervention for increasing tobacco use treatment and quit rates among household members who smoke versus a treatment as usual group. This clinical trial also aims to study household member and pediatric patient characteristics that are associated with reach and effectiveness of Refer2Quit.",[26,27,28],"Smoking","Smoking Cessation","Second Hand Tobacco Smoke",[26,27,28],"RECRUITING","2026-08-04",{"date":33,"type":34},"2026-08-06","ACTUAL",{"date":36,"type":34},"2024-09-06",{"date":38,"type":20},"2027-03-01",{"name":40,"class":41},"Children's Hospital of Philadelphia","OTHER",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":42},"100549926","phase-1-calculating-wall-shear-stress-in-infant-pulmonary-veins-100549926","NCT06440408","Calculating Wall Shear Stress in Infant Pulmonary Veins","Calculating Wall Shear Stress in Pulmonary Veins of Infants Using Cardiac Magnetic Resonance Imaging: A Pilot Study","PVS-WSS","Normal (Controls) Subjects Inclusion Criteria\n\n1. Males or Females less than 18 years of age.\n2. Weight \\> 3 kg.\n3. Undergoing cMRI with ferumoxytol as part of clinical care.\n4. Structurally normal heart (by echocardiography) with exception of small left to right shunts, isolated valve pathology, anomalous coronary arteries, extracardiac vascular anomalies such as arch anomalies.\n5. Parental\u002Fguardian permission (informed consent).\n\nNormal (Controls) Subjects Exclusion Criteria\n\n1. Congenital heart disease (except small left to right shunts, isolated valve pathology, anomalous coronary arteries, extracardiac vascular anomalies such as arch anomalies).\n2. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n3. Patient not receiving ferumoxytol as part of their cMRI due to a known hypersensitivity to the drug, or a known diagnosis of iron overload.\n\nHigh-Risk Subject Inclusion Criteria\n\n1. Males or Females less than 12 months of age.\n2. Diagnosis of severe BPD (group 1) or TAPVC s\u002Fp repair (group 2).\n3. Weight \\> 3 kg.\n4. Receiving respiratory support with an invasive airway (tracheostomy or endotracheal tube) (group 1 only).\n5. Undergoing cMRI with ferumoxytol as part of clinical care (group 2 only).\n6. Parental\u002Fguardian permission (informed consent).\n\nHigh-Risk Subject Exclusion Criteria\n\n1. Congenital heart disease with single ventricle physiology.\n2. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n3. Patient has a contraindication to ferumoxytol or any intravenous iron product such as a known hypersensitivity to the drug, or a known diagnosis of iron overload.",{"count":52,"type":20},20,[54],"PHASE1","The purpose of this study is to better understand pediatric pulmonary vein stenosis (PVS), which is the narrowing of blood vessels that connect the lungs to the heart. PVS is a life-threatening disease without a clear cause. The investigators think patients who develop PVS have an increased Wall Shear Stress (WSS) level in the pulmonary veins, which is the force placed on the walls of the veins. This study will determine if WSS can be calculated in the pulmonary veins of infants using Ferumoxytol enhanced Cardiac Magnetic Resonance Imaging (FcMRI). If possible, the investigators aim to use FcMRI to better screen patients at risk of PVS and to help guide therapy in patients with PVS.",[57],"Pulmonary Vein Stenosis",[59,60],"Cardiac Magnetic Resonance Imaging","Wall Shear Stress","2026-08-03",{"date":63,"type":34},"2026-08-05",{"date":65,"type":34},"2024-09-30",{"date":67,"type":20},"2028-06",{"name":40,"class":41},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":42},"100552660","multidimensional-phenotype-classification-in-grade-3-bronchopulmonary-dysplasia-100552660","NCT06475976","Multidimensional Phenotype Classification in Grade 3 Bronchopulmonary Dysplasia","Inclusion Criteria (infant subjects):\n\n* Male or female infant born with gestational age \\\u003C32 weeks\n* Postmenstrual age between 36-65 weeks at enrollment\n* Receiving invasive ventilation at enrollment\n* Grade 3 BPD or grade 2 BPD with need for chronic invasive ventilation at enrollment\n* Parental informed consent (provides the consent to participate)\n\nExclusion Criteria (infant subjects):\n\n* Contraindication to 1 or more of the study diagnostic procedures\n* Family unable\u002Funlikely to commit to 2-year follow-up\n* Unlikely to survive the 6-8-week diagnostic period\n* Parental consent not provided (decline consenting for study)\n* Aneuploidy or other severe congenital abnormality not-representative in BPD\n\nAt the time of consent, a parent or guardian caregiver will be invited to participate as an enrolled dyad using the following eligibility criteria:\n\nInclusion criteria (parents\u002Fguardians):\n\n* Parent or legal guardian of an enrolled infant subject\n* Informed consent\n\nExclusion criteria (parents\u002Fguardians):\n\n* Unable\u002Funlikely to complete study procedures","1 Month","1 Year",{"count":78,"type":20},130,"OBSERVATIONAL","Bronchopulmonary Dysplasia (BPD), or chronic lung disease of prematurity, is the most consequential complication of preterm birth and is strong predictor of childhood pulmonary and neurodevelopmental disability, particularly in infants diagnosed with grade 3 BPD (ventilator dependence at 36 weeks' postmenstrual age), the most severe disease form. This study aims to (1) generate the first empirically defined phenotype classification system for grade 3 BPD developed using a rich array of objective and quantitative cardiopulmonary diagnostic, clinical, and biological data; and (2) define the association between phenotype subgroups and neurodevelopmental and respiratory outcomes through 2 years' corrected age.",[82],"Bronchopulmonary Dysplasia",[82,84,85],"BPD","Multidimensional Phenotype","2026-07-27",{"date":88,"type":34},"2026-07-28",{"date":90,"type":34},"2023-12-05",{"date":92,"type":20},"2029-07-31",{"name":40,"class":41},{"id":95,"slug":96,"hasResults":12,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":12,"sex":16,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":110,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":42},"100569400","phase-2-ceus-evaluation-of-hydrocephalus-in-neonates-and-infants-100569400","NCT06693752","CEUS Evaluation of Hydrocephalus in Neonates and Infants","Pilot Study of Improved Diagnosis and Monitoring of Hydrocephalus in Neonates and Infants Using Contrast-Enhanced Ultrasound","Inclusion Criteria:\n\n1. Males and females younger than 1.5 years old with diagnosed and\u002For suspected hydrocephalus.\n2. Post menstrual age of 26 weeks or older.\n3. Inpatients at the Children's Hospital of Philadelphia.\n4. Parental\u002FLegally authorized representative permission.\n\nExclusion Criteria:\n\n1. Medical history of Lumason hypersensitivity.\n2. Hemodynamic instability as defined by rapid escalation of cardiopulmonary support in the past 12-24 hours, as defined by the clinical care team.\n3. Respiratory instability as defined by rapid escalation of respiratory support in the past 12-24 hours (Increased fraction of inspired oxygen (FiO2) requirement and\u002For nitric oxide).","1 Minute","18 Months",{"count":52,"type":20},[105],"PHASE2","Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to assess the safety and feasibility of performing brain contrast-enhanced ultrasound (CEUS) in neonates and infants with diagnosed and\u002For suspected hydrocephalus.",[108,109],"Hydrocephalus in Infants","Hydrocephalus Acquired",[111,112,113],"Ultrasound","Contrast-enhanced ultrasound","Infant hydrocephalus","2026-07-23",{"date":116,"type":34},"2026-07-24",{"date":118,"type":20},"2026-08-15",{"date":120,"type":20},"2028-08-01",{"name":40,"class":41},{"id":123,"slug":124,"hasResults":12,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":12,"sex":16,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":141,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":143,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":149},"100551280","phase-2-selpercatinib-pre-rai-in-patients-with-ret-fusion-thyroid-cancer-raise-100551280","NCT06458036","Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)","Selpercatinib to Enhance RAI Avidity in Children, Adolescents, and Young Adults With Newly Diagnosed Differentiated Thyroid Cancers Harboring RET Fusions","RAISE","Inclusion Criteria:\n\n1. Age 2-25 years, inclusive\n2. Histologic diagnosis of a differentiated thyroid cancer, status post thyroidectomy and adequate local therapy (e.g., lymph node dissection as per standard of care) for metastatic disease in the neck in the opinion of the treating investigator\n3. Anatomically evaluable disease on chest CT (Computed Tomography) meeting one of the following criteria (obtained within 90 days of enrollment):\n\n   A. multiple (\\> 10) noncalcified solid pulmonary nodules visible on CT and\u002For B. enlarging, discrete pulmonary nodules visible on CT of any number consistent with metastatic disease\n4. Identification of an activating RET gene alteration (fusion or mutation). The RET alteration result should be generated from a laboratory with specific certifications (depending on country requirement) that clearly denotes the presence of a RET alteration without known kinase domain resistance mutation\n5. Lansky\u002FKarnofsky performance status \\>50%\n6. Adequate Organ Function\n\n   A. Bone Marrow Function:\n   * Peripheral absolute neutrophil count (ANC) ≥1500\u002FµL\n   * Platelet count ≥ 100,000\u002FµL (transfusion independent, defined as not receiving platelet transfusions for at least 7 days prior to enrollment)\n   * Hemoglobin ≥ 9.0 g\u002FdL at baseline (may receive Red Blood Cell transfusions).\n\n   B. Adequate Renal Function: Creatinine clearance or radioisotope Glomerular Filtration Rate (GFR) ≥ 70 mL\u002Fmin\u002F1.73 m2 or a maximum serum creatinine based on age\u002Fgender.\n\n   C. Adequate Liver Function\n   * Bilirubin (sum of conjugated + unconjugated) \\\u003C \u002F = 1.5 x upper limit of normal (ULN) for age. Except participants with a documented history of Gilbert syndrome who must have a total bilirubin level of \\\u003C3.0X ULN\n   * Alanine aminotransferase (ALT) \\\u003C2.5X ULN OR \\\u003C5x ULN if the liver has tumor involvement. For the purpose of this study, the ULN for ALT is 45 U\u002FL.\n   * Serum albumin ≥ 2 g\u002FdL\n7. Patient must have normal serum potassium, calcium, and magnesium levels (may be receiving supplements)\n8. Men with partners of childbearing potential or women of childbearing potential must agree to use a highly effective contraceptive method during treatment with study drug and for 6 months following the last dose of study drug. Selpercatinib could impair fertility in males and females. Advise women not to breastfeed during treatment with selpercatinib and for 1 week following the final dose\n9. Women of childbearing potential must have a negative pregnancy test (serum or urine, consistent with local regulations) documented within 24 hours prior to treatment with study drug and at least monthly while on study treatment\n\nExclusion Criteria:\n\n1. No prior systemic therapy for thyroid cancer, including RET inhibitors. Note: prior 131I is allowed.\n2. Females who are pregnant or breastfeeding are excluded due to the potential risks of selpercatinib and radioactive iodine to the fetus\u002Fneonate.\n3. Concurrent therapy: Patients currently receiving a strong CYP3A4 inducer or inhibitor are not eligible. Strong inducers or inhibitors of CYP3A4 should be avoided 14 days prior to treatment to the end of the study treatment.\n4. Patients with clinically significant active cardiovascular disease, Torsades de pointes, or history of myocardial infarction within 6 months prior to planned start of study treatment or prolongation of the QT interval corrected for heart rate using Fridericia's formula (QTcF) \\>470 msec.\n5. Have clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal absorption of the drug.\n6. Are taking a concomitant medication that is known to cause QTc prolongation.\n7. Active hemorrhage or at significant risk for hemorrhage.\n8. Uncontrolled hypertension (blood pressure greater than 140\u002F90 in adults or greater than the 95% for height and gender in children). Use of anti-hypertensives to control blood pressure is permitted.","2 Years","25 Years",{"count":133,"type":20},13,[105],"Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.",[137,138,139,140],"Differentiated Thyroid Cancer","Pediatric Cancer","Cancer","Cancer, Thyroid",[142],"Thyroid Cancer",{"date":116,"type":34},{"date":145,"type":34},"2024-07-29",{"date":147,"type":20},"2031-11-01",{"name":40,"class":41},5,{"id":151,"slug":152,"hasResults":12,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":157,"sex":16,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":42},"100607686","examining-the-efficacy-of-the-praise-with-coaching-program-100607686","NCT07191782","Examining the Efficacy of the PRAISE With Coaching Program","Examining the Efficacy of the PRAISE With Coaching Program in Reducing Peer Aggression and Bullying","Student Inclusion Criteria:\n\n* Enrolled in one of the participating school sites\n* In a 3rd-5th grade classroom participating in the study\n\nStaff Inclusion Criteria:\n\n* Employed by one of the participating school sites\n* Teach and\u002For provide services to students in 3rd-5th grade\n\nStudents Exclusion Criteria:\n\n* Do not speak English\n* Special education students not integrated in a regular education classroom\n* Student not in Grades 3-5 at the participating school sites\n\nTeacher Exclusion Criteria:\n\n* Do not speak English\n* Do not teach\u002Fprovide services with 3rd-5th grade students at the participating school sites",true,"8 Years",{"count":160,"type":20},1008,[23],"The PReventing Aggression In Schools Everyday (PRAISE) Program has evidence of impact when run by research staff. PRAISE was adapted using community-based participatory research to a coaching model whereby school-staff are trained to facilitate the program and receive ongoing coaching from research staff. The overall objective is to demonstrate the efficacy of the adapted PRAISE program when facilitated by in-school staff.",[164,165,166],"Aggression Childhood","Bullying Victimization","Social Behavior",[168,169,170,171,172,173],"late elementary school","universal classroom-based","aggression prevention","bullying prevention","relational aggression","coaching","2026-07-21",{"date":176,"type":34},"2026-07-22",{"date":178,"type":34},"2025-09-26",{"date":180,"type":20},"2028-12-30",{"name":40,"class":41},{"id":183,"slug":184,"hasResults":12,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":16,"minAge":189,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":192,"briefSummary":193,"conditions":194,"keywords":197,"overallStatus":203,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":42},"100648219","observational-approach-versus-surgical-intervention-for-stones-100648219","NCT07718802","Observational Approach Versus Surgical Intervention for Stones","OASIS","Inclusion Criteria:\n\n1. Individuals age 6 or older\n2. Diagnosis of kidney stone disease (nephrolithiasis)\n3. Asymptomatic, non-obstructive kidney stones measuring 4 to 10 mm (inclusive)\n\n   * Asymptomatic is defined as the absence of abdominal pain, flank pain, gross hematuria, and nausea and\u002For vomiting in the last 3 months that in the judgement of the site PI could be attributable to kidney stones.\n   * Non-obstructive is defined as a stone in a renal calyx or stones in multiple renal calyces on CT, ultrasound, and\u002For x-ray obtained within 6 months of screening.\n4. Informed consent and if appropriate, child assent.\n5. Willingness to be randomized to surgery or observation Note: subjects otherwise eligible who decline randomization may be enrolled in a parallel observational cohort.\n6. Fluent in English or Spanish\n7. Willingness to be audio- and\u002For video- recorded during interviews\n\nExclusion Criteria:\n\n1. Untreated hydronephrosis or caliectasis\n2. Pain (e.g., renal colic, abdominal pain) or gross hematuria attributed to kidney stones.\n3. Recurrent symptomatic urinary tract infections (≥3 in 12 months or ≥2 in 6 months). A symptomatic urinary tract infection is defined as having at least one bladder or voiding symptom (e.g., frequency, urgency, dysuria) with bacteriuria (≥105 colony forming units\u002FmL of no more than 2 urinary tract pathogens).\n4. Stone in the renal pelvis, ureter, bladder or urethra\n5. Pregnant females\n6. Solitary kidney, transplant kidney, urinary diversion, medullary sponge kidney\n7. Anatomic abnormality of the kidney (e.g., horseshoe kidney)\n8. Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures","6 Years",{"count":191,"type":20},1658,[23],"The aims of the Observational Approach versus Surgical Intervention for Asymptomatic Stone (OASIS) trial are: 1) to determine whether observation compared to upfront surgery results in less healthcare-related life disruption due to kidney stones among children and adults with asymptomatic kidney stones; 2) to identify the groups benefiting the most from each strategy; and 3) to determine the preferences and values informing the choice between observation and upfront surgery.",[195,196],"Nephrolithiasis","Kidney Stone",[198,199,200,201,202],"kidney stones","kidney","nephrolithiasis","Comparative Effectiveness","Patient Reported Outcomes","NOT_YET_RECRUITING","2026-07-16",{"date":176,"type":34},{"date":207,"type":20},"2026-08-01",{"date":209,"type":20},"2032-10-01",{"name":40,"class":41},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":218,"enrollmentInfo":219,"targetDuration":4,"studyType":21,"phases":221,"briefSummary":222,"conditions":223,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},"100557149","transpyloric-versus-gastric-feeding-in-bronchopulmonary-dysplasia-100557149","NCT06534359","Transpyloric Versus Gastric Feeding in Bronchopulmonary Dysplasia","Pilot Trial Comparing Transpyloric to Gastric Feeding in Very Preterm Infants With Bronchopulmonary Dysplasia","Inclusion Criteria:\n\n1. Birth \\\u003C32 weeks' gestation\n2. Current postmenstrual age of 36-65 weeks\n3. Grade 2-3 bronchopulmonary dysplasia (BPD: treatment with positive airway pressure at 36 weeks' PMA) or grade 1 BPD (treatment with ≤2L\u002Fmin flow nasal cannular at 36 weeks' PMA) with subsequent need for prolonged positive airway pressure and full enteral tube feedings\n4. Treatment with positive airway pressure (high flow nasal cannula, non-invasive positive airway pressure, or invasive ventilation) at enrollment\n\n(4) Full gastric tube feedings (≥100mL\u002Fkg\u002Fd) at the time of enrollment (5) Parental consent to participate\n\nNote: At least 20 infants receiving invasive ventilation will be enrolled to enable endotracheal biomarker testing.\n\nExclusion Criteria:\n\n1. Transpyloric feedings received within 7d of enrollment\n2. Use of a gastric acid suppression, GI promotility drug, or caffeine within 7d of enrollment\n3. History of gastrostomy tube placement, gastric fundoplication, or bowel resection resulting in short gut with contraindication to transpyloric feeding\n4. Plan to wean off positive airway pressure (for non-intubated subjects) or to be extubated to non-invasive support (for subjects receiving invasive ventilation) within the 2wk trial\n5. Known intolerance to transpyloric feeding\n6. Persistent \\>20% endotracheal tube leak (for intubated subjects only)\n7. Active treatment with an investigational therapy as part of another interventional trial\n8. severe congenital or genetic abnormality that adversely affects GI or cardiopulmonary function","12 Months",{"count":220,"type":20},60,[23],"The goal of this clinical trial is to learn if transpyloric tube feeding (feeding directly into the small intestine) versus gastric tube feeding tolerably and effectively reduces gastroesophageal reflux in infants born premature who have been diagnosed with bronchopulmonary dysplasia. The main questions this trial aims to answer are:\n\nDoes transpyloric as compared to gastric tube feeding result in differences in the amount of experienced hypoxemia (low oxygen level in the blood) or serious adverse events?\n\nDoes transpyloric as compared to gastric tube feeding reduce the frequency and severity of gastroesophageal reflux (GER) measured using 24 hour esophageal pH-multichannel intraluminal impedance (pH-MII) monitoring?\n\nParticipants will:\n\nUndergo pre-trial 24 hour pH-MII monitoring to determine baseline severity of GER.\n\nBe randomly assigned to receive transpyloric or gastric tube feeding for 2 weeks.\n\nUndergo repeat pH-MII at the end of the 2 week trial to assess for change in GER.\n\nUndergo continuous pulse oximetry to record level of hypoxemia during the 2 week trial.\n\nUndergo saliva and airway (if supported by a breathing tube) fluid collection to measure biomarkers of GER.\n\nBe monitored clinically for possible adverse events.",[82,224],"Gastroesophageal Reflux",{"date":226,"type":34},"2026-07-17",{"date":228,"type":34},"2025-07-15",{"date":230,"type":20},"2027-06-30",{"name":40,"class":41},4,{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":16,"minAge":240,"maxAge":241,"enrollmentInfo":242,"targetDuration":4,"studyType":21,"phases":244,"briefSummary":245,"conditions":246,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":42},"100647488","removing-surrogates-uncertainty-to-reduce-fear-and-anxiety-after-cardiac-events---kids-100647488","NCT07707037","Removing Surrogates Uncertainty to Reduce Fear and Anxiety After Cardiac Events - Kids","RESURFACE-Kids","Inclusion Criteria:\n\nCaregiver\n\n1. Caregiver of a child \\\u003C17.5 years of age who had at least a 2 minute cardiac arrest, is expected to be discharged within 30 days, and to survive at least 3 months post-discharge from hospital.\n2. English speaking\n\nChild\n\n1. \\\u003C17.5 years of age\n2. Have had a cardiac arrest lasting more than 2 minutes within the past 7 days and have not yet been discharged from pediatric intensive care unit (PICU) or cardiac intensive care unit (CICU)\n\nExclusion Criteria:\n\n1\\) Parent or legal guardian is not the child's caregiver","0 Days","17 Years",{"count":243,"type":20},30,[23],"This pilot randomized controlled trial (RCT) will test the feasibility and acceptability of the informational intervention program, Heartsight, to reduce caregivers' uncertainty experienced throughout their child's illness trajectory after cardiac arrest. The investigator aims to enroll up to 30 caregivers of pediatric cardiac arrest patients to (Aim 1a) pilot recruitment and randomization (2:1) procedures, and (Aim 1b) estimate retention rate at 3 months and assess engagement and utilization metrics for frequency of access and time spent on each module of the informational packages. The investigator also aims to evaluate the association of the intervention with efficacy outcomes in an exploratory manner in preparation for a larger trial, including (Aim2a) a preliminary estimate of the association of intervention with the surrogate's uncertainty levels at 3 months post-discharge, and (Aim 2b) a preliminary estimate of the association of intervention with the surrogate's anxiety, depression, and post-traumatic stress symptoms at 3 months post-discharge.",[247,248,249],"Cardiac Arrest","Anxiety Depression","Family Support","2026-07-10",{"date":204,"type":34},{"date":253,"type":34},"2026-06-01",{"date":255,"type":20},"2027-05-31",{"name":40,"class":41},{"id":258,"slug":259,"hasResults":12,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":4,"eligibilityCriteria":263,"healthyVolunteers":157,"sex":16,"minAge":264,"maxAge":17,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":42},"100472497","fiber-food-introduction-in-pediatric-short-bowel-syndrome-100472497","NCT05432648","Fiber Food Introduction in Pediatric Short Bowel Syndrome","Clinical Tolerance and Microbiome Changes Following Fiber Food Introduction in Short Bowel Syndrome","Inclusion Criteria:\n\n* Actively follows at the Children's Hospital of Philadelphia (CHOP) outpatient clinics\n* SBS arm specific: History of SBS diagnosis. History of short bowel syndrome based on surgical\u002Fimaging records. Small bowel is in continuity with some portion of colon\n* Control arm specific: No history of intestinal pathologies\n* No or negligible amount (few bites of fiber-containing foods okay) of fiber in tube feeds or by mouth at baseline\n* Less than 20% calories from oral food not containing fiber while the other 80% may be by enteral and\u002For parenteral feedings\n* At least 20% calories from fiber-free formula taken orally or via tube\n* Antibiotic use is allowed, however, should be on a stable regimen of antibiotics starting from 2 weeks prior to intervention until end of study or end of week 3 whichever is sooner. Instances of antibiotic use for brief courses (7-10 days) as long as sample collection is scheduled to be at least a week from the end date of antibiotics.\n* Previous history of fiber introduction failure is acceptable as long as clinically stable at the time of recruitment\n* Fiber supplementation is appropriate per primary physician\n* If subject is unable to provide full set of samples, they will still be enrolled\n\nExclusion Criteria:\n\n* SBS Arm specific: No diagnosis of SBS.\n* Control Arm specific: has baseline intestinal diseases\n* Small bowel and colon not in continuity (Ex: presence of ileostomy or jejunostomy)\n* \\>5% changes in percentage of calories from oral nutrition (PO), enteral nutrition (EN) and\u002For parenteral nutrition (PN) during the intervention\n* Addition\u002Fdiscontinuation\u002Fsignificant alteration to antibiotics regimen during study period\n* Primary physician does not think fiber supplementation is appropriate clinically","4 Months",{"count":220,"type":20},[23],"Short bowel syndrome (SBS) is a rare but challenging condition in which patients have insufficient bowel length to meet fluid, electrolyte, and nutrient requirements without parenteral support.\n\nThe purpose of this study is to determine how well dietary fiber is tolerated in patients with short bowel syndrome compared to patients without short bowel syndrome based on assessment of gastrointestinal symptoms, and corresponding changes in microbiome composition and metabolomics.",[269],"Short Gut Syndrome","2026-07-09",{"date":250,"type":34},{"date":273,"type":34},"2022-05-08",{"date":275,"type":20},"2027-10",{"name":40,"class":41},{"id":278,"slug":279,"hasResults":12,"nctId":280,"briefTitle":281,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":16,"minAge":284,"maxAge":17,"enrollmentInfo":285,"targetDuration":4,"studyType":21,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":42},"100565443","sleep-promotion-and-pediatric-hypertension-100565443","NCT06642246","Sleep Promotion and Pediatric Hypertension","Sleep Promotion Among Children Newly Diagnosed With Essential Hypertension","Inclusion Criteria:\n\n* Speak, read and write in English.\n* Parental\u002Fguardian permission (informed consent) and child assent.\n* Have a computer or a tablet computer with access to the Internet or own a smartphone with a data and text plan.\n* Parent reported sleep duration on school nights less than or equal to 7.5 hours.\n* Recently diagnosed with essential hypertension by Ambulatory Blood Pressure Monitoring (ABPM).\n* If taking over the counter sleep aides, willing to stop them over the course of the study.\n\nExclusion Criteria:\n\n* Any clinically diagnosed sleep disorder (e.g. sleep apnea) in the electronic health record and or regular use of prescribed sleep aide.\n* Underlying chronic medical conditions, defined as a medical condition with a duration or expected duration longer than 3 months that involved taking regular medication, taking medications that could affect blood pressure (e.g., anti-hypertensive medications, glucocorticoids, or stimulants), and patients with underlying diagnoses known to be associated with elevated blood pressure (e.g., cardiac disease, kidney disease or diabetes).\n\nInclusion Criteria for Parents\u002FLegal Guardians:\n\n* Be the parent\u002Fguardian of an eligible child enrolled in the main study.\n* Speak, read, and write in English.\n\nExclusion Criteria for Parents\u002FLegal Guardians:\n\n\\- Limited English proficiency","13 Years",{"count":286,"type":20},10,[23],"Determine the effectiveness and feasibility of a mobile health sleep extension approach in the pediatric nephrology setting, to increase sleep duration and reduce systolic and diastolic blood pressure.",[290,291],"Insufficient Sleep","Hypertension",[290,291],"2026-07-06",{"date":295,"type":34},"2026-07-07",{"date":297,"type":34},"2026-02-16",{"date":299,"type":20},"2026-09",{"name":40,"class":41},{"id":302,"slug":303,"hasResults":12,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":131,"enrollmentInfo":308,"targetDuration":4,"studyType":21,"phases":310,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":42},"100347932","cd45ra-depleted-peripheral-stem-cell-addback-for-viral-or-fungal-infections-post-tcrcd19-depleted-hsct-100347932","NCT03810196","CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ\u002FCD19 Depleted HSCT","CD45RA Depleted Peripheral Stem Cell Addback for Patients at Risk for Viral or Fungal Infections Post TCRαβ\u002FCD19 Depleted Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n1. Age: Patients \\\u003C25 years.\n2. First allogeneic HSCT only.\n3. Disease eligibility: Acute leukemias at high risk for relapse including positive minimal residual disease at end consolidation, high risk cytogenetics, or relapse. Hematologic malignancies including: acute myeloid leukemia, myelodysplastic syndromes, acute lymphoblastic leukemia, mixed lineage or bi-phenotypic leukemia, lymphoblastic or Burkitts, juvenile myelomonocytic leukemia\n4. Evaluation of organ and infectious status as per our Bone Marrow Transplant standard operating procedure (BMT SOP).\n5. Signed consent by parent\u002Fguardian or able to give consent if \\>18 years.\n\nExclusion Criteria:\n\n1. Patients who do not meet institutional disease, organ or infectious criteria\n2. No suitable donor available for mobilized peripheral stem cells\n3. Patients with genetic disorders including Fanconi anemia, Kostmann syndrome, dyskeratosis congenital or other DNA repair defects.\n4. Patients with Hodgkin lymphoma or non-Burkitts, non-lymphoblastic lymphoma\n5. Pregnant Participants\n\nDonor selection and eligibility\n\n1. Unrelated donor meets National Marrow Donor Program criteria for donation\n2. HLA testing\u002Fmatching\n3. Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection",{"count":309,"type":20},50,[23],"The major morbidities of allogeneic hematopoietic stem cell transplant with non-human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life threatening infections. T depletion of the donor hematopoietic stem cell graft is effective in preventing GVHD, but immune reconstitution is slow, increasing the risk of infections. An addback of donor CD45RA (naive T cells) depleted cells may improve immune reconstitution and help decrease the risk of infections.",[313,314,315,316,317,318,319,320],"Acute Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndromes","Acute Lymphoblastic Leukemia","Mixed Lineage Leukemia","Lymphoblastic Lymphoma","Burkitt Lymphoma","Juvenile Myelomonocytic Leukemia","2026-07-05",{"date":323,"type":34},"2026-07-08",{"date":325,"type":34},"2019-03-01",{"date":327,"type":20},"2028-07",{"name":40,"class":41},{"id":330,"slug":331,"hasResults":12,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":336,"phases":4,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":342,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":343,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":344,"locationsCount":42},"100296942","expanded-access-protocol-using-alphabeta-t-and-cd19-depleted-pbsc-100296942","NCT03145545","Expanded Access Protocol Using Alpha\u002FBeta T and CD19+ Depleted PBSC","Expanded Access Protocol Using TCR Alpha\u002FBeta T Cell\u002FCD19+ Depleted Donor Peripheral Stem Cells","PATIENT AND DONOR ELIGIBILITY\n\nEnrollment on this study includes patients undergoing a primary or non emergent subsequent hematopoietic stem cell transplant, an urgent subsequent transplant in the setting of graft failure or marrow aplasia, or an unconditioned stem cell boost for graft dysfunction or declining donor chimerism. Differences in eligibility criteria among these scenarios are outlined below.\n\nInclusion Criteria: Applicable to all Subjects\n\n* Signed, informed consent\n* Participants of childbearing potential must have a negative pregnancy test as per institutional SOP\n* Patients who do not meet criteria for current open, institutional protocols using CliniMACs device for β T\u002FCD19+ depletion\n* Patients with the following transplantable diseases:\n\n  * Non-malignant diseases\n  * Metabolic storage diseases correctable by HSCT\n  * Bone marrow failure syndromes\n  * Immunodeficiencies\u002Fimmune dysregulation syndromes\n  * Sickle cell disease or thalassemia\n  * Other diseases treated with HSCT\n\n    o Malignant diseases\n  * Acute leukemias\n  * Chronic leukemias\n  * Lymphomas\n  * Myelodyplastic syndrome\n\nInclusion Criteria: Primary transplant or non-emergent subsequent transplant\n\nThe conditioning prescribed to the patient will be determined based on the disease and organ status and will include agents that are standard. Appropriate combinations of chemotherapy, immunotherapy and\u002For radiation will be determined on an individual basis. Patient eligibility will be assessed as per our current institutional standard operating procedures. Patients that meet the following criteria may be eligible:\n\n* Lansky or Karnofsky performance ≥ 60\n* Hematologic and Organ Function as per current institutional SOP\n* Infectious Evaluation as per current institutional SOP\n\nInclusion Criteria: Urgent subsequent transplant, with conditioning, in the setting of graft failure or severe marrow dysfunction\n\nFor subjects undergoing an urgent subsequent transplant, conditioning will be individualized based on the underlying disease, prior transplant history, and current organ function. Subjects with the following may be eligible:\n\n* Adequate organ function as determined by the transplant physician to safely tolerate the planned conditioning regimen\n* No active, uncontrolled infection\n* Patients whose initial transplant was performed under this protocol, under another clinical protocol, or using a bone marrow graft\n* Previously collected TCRαβ\u002FCD19 depleted stem cells from this or another approved protocol may be used if available.\n\nInclusion Criteria: Unconditioned Stem Cell Boost\u002FTransplant These subjects will not be required to meet the performance status, hematologic and organ function, or infectious evaluation criteria listed above, as conditioning will not be administered.\n\n* Patients with cytopenias due to bone marrow dysfunction, declining donor chimerism, or other treatment needs as determined by the subject's clinical course\n* Patients with active infections are eligible, as the stem cell boost will be administered without conditioning\n* Previously collected TCRαβ\u002FCD19 depleted stem cells from this or another approved protocol may be used if available.\n* Patients who received their initial transplant either on this protocol or on a separate protocol\n\nExclusion Criteria: Applicable to all Subjects\n\n* Suitable and available HLA matched sibling donor. However, patients with fully matched related donors (including siblings) may be eligible in special circumstances where use of an unmanipulated bone marrow graft has increased risks for donor or recipient.\n* Donor unable to donate peripheral stem cells\n* Pregnant participants\n\nDonor Eligibility Patients must have an identified living donor\n\n* Donor selection will comply with 21 CFR 1271\\*\n* Unrelated donor that meets the matching criteria of the NMDP with allele matching at HLA -A, -B, -C, -DRB1, and -DQB1: Unrelated donors may be a 10\u002F10 match, a 9\u002F10 match, or an 8\u002F10 match if one of the mismatches is at DQB1.\n* Related donor mismatched at one to five HLA alleles (haploidentical)\n* Matched related donor may be considered suitable donors for this protocol if a peripheral stem cell donation is deemed by the clinical team to be a safer donation option (if donor is not a suitable candidate for a bone marrow harvest) or if there is concern that bone marrow harvest would not yield adequate cell doses Additionally, a matched related donor would be considered suitable for this protocol if there are safety concerns regarding a patient receiving a standard T cell replete bone marrow transplant due to individualized GVHD risk or risk related to standard GVHD prevention medications.\n* Donor suitable for mobilization of peripheral stem cells and apheresis and fulfills infectious disease criteria as per our institutional SOP, including HIV, HepB, HepC PCR negative.\n* We assess donor eligibility as per our Allogenic Donor Evaluation for Eligibility standard operating procedure. These procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. Our donor collection program is FACT accredited.\n* Related donors will be consented and enrolled under IRB approved research protocol for cell collection per IRB 04-004078 CHP 784 Clinical and Research Collection and Future Research Use of Bone Marrow, Stem Cells or T Cells.\n* Unrelated donor identified through the National Marrow Donor Program (NMDP) and fulfills the NMDP criteria for donation. Unrelated donor willing and able to undergo mobilization of peripheral stem cells and apheresis.\n* The donors selected for this IDE will either be unrelated donors identified through the National Marrow Donor Program (NMDP) or related donors. Regarding the unrelated donors, NMDP procedures for determining donor eligibility include donor screening and testing for relevant communicable disease agents and diseases","EXPANDED_ACCESS","The primary objective of this protocol is to expand access for patients who lack a fully HLA (Human leukocyte antigen) matched sibling donor, and who are candidates for allogeneic hematopoietic stem cell transplant (HSCT). These patients have a serious or immediately life-threatening disease for which HSCT is indicated. These patients are not eligible for other Children's Hospital of Philadelphia Institutional Review Board (IRB) approved protocols that utilize CliniMACs technology for T depletion.",[339,340,341],"Leukemia","Bone Marrow Failure Syndrome","Immunodeficiencies","AVAILABLE",{"date":323,"type":34},{"name":40,"class":41},{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":4,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":16,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":21,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":42},"100378899","sleep-and-glycemic-control-in-type-2-diabetes-adolescents-100378899","NCT04213547","Sleep and Glycemic Control in Type 2 Diabetes Adolescents","Sleep Duration and Glycemic Control in Adolescents With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\nAim 1 for child:\n\n1. Subjects age 12-20\n2. Diagnosed with T2DM by standard laboratory criteria without pancreatic autoimmunity\n3. Low probability of obstructive sleep apnea (OSA) assessed via validated sleep survey\n4. Subjects will be included if they are taking T2DM treatments (i.e., diet modification, Metformin and\u002For insulin)\n5. Parental\u002Fguardian permission and child assent\n\nAim 1 for parent:\n\n1\\. Parent or legal guardian of child that meets inclusion criteria for Aim 1.\n\nAim 2 for child:\n\n1. Completed Aim 1 evaluation\n2. Average sleep duration \\\u003C 8 hours per night as determined by actigraphy in Aim 1\n3. HbA1c ≤ 10% as HbA1c \\>10 correlates to poor adherence\n4. Adherence \\> 80%\n\nFocus group for child:\n\n1. Subjects aged 12-20\n2. Diagnosed with type 2 diabetes without pancreatic autoimmunity\n\nExclusion Criteria:\n\nAim 1 for child:\n\n1. Non-English speaking subject (as questionnaires used are validated in English)\n2. Institutionalized patients as sleep duration will not be of their own accord, and therefore is not generalizable to the rest of the adolescent T2DM population.\n3. Patients with other forms of Diabetes Mellitus (e.g. Type 1 Diabetes)\n4. Behavioral disorders that may affect data collection (e.g. autism spectrum disorder) will be determined on a case-by-case basis. These include patients that are unable to answer questionnaires on their own, participate in a sleep diary, wear devices and\u002For understand incentives.\n5. Oral or IV steroid treatment within the past month\n6. Females with known pregnancies as these patients will not be generalizable to the rest of the adolescent T2DM population and pregnancy may alter sleep duration.\n7. Subjects with known hyperthyroidism, pain syndrome, or serious medical condition that can affect sleep.\n8. Subjects with hemoglobinopathies that affect hemoglobin A1c measurement.\n9. Unable to obtain point-of-care hemoglobin A1c in clinic on date of recruitment\n10. Known diagnosis of obstructive sleep apnea or other sleep disorder\n\nAim 1 for Parent:\n\n1. Non-English speaking subject (as questionnaires used are validated in English)\n2. Parent\u002Fguardians with cognitive disorders that may affect data collection (determined on a case-by-case basis)\n\nAim 2 for child:\n\n1\\. Do not own a smart phone or tablet\n\nFocus group for child:\n\n1. Non-English speaking subject (as focus group will be conducted in English)\n2. Lack of access to a computer, tablet or smartphone that can accommodate participation in video conferencing","12 Years","20 Years",{"count":355,"type":20},90,[23],"The primary objective is to determine the cross-sectional relationship between sleep duration (as measured by 14 days of actigraphy) and glycemic control in an adolescent Type 2 Diabetes (T2DM) cohort (age 12-20y, n=67). A secondary objective is to determine if a loss-framed incentive for achieving sleep goals can increase sleep duration in 15 adolescent patients diagnosed with T2DM with insufficient sleep. Another secondary objective is to test if increasing sleep duration leads to improved glycemic control in 15 adolescents with T2DM identified in Aim 1 as having \\\u003C8 hr sleep\u002Fevening. A focus group will be conducted prior to this intervention with patients ineligible for the intervention in order to determine appropriate text messaging.",[359],"Type 2 Diabetes","2026-06-25",{"date":362,"type":34},"2026-06-29",{"date":364,"type":34},"2020-09-16",{"date":366,"type":20},"2028-07-01",{"name":40,"class":41},{"id":369,"slug":370,"hasResults":12,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":17,"enrollmentInfo":374,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":376,"conditions":377,"keywords":379,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":42},"100317946","electrographic-seizure-management-and-neurobehavioral-outcomes-in-critically-ill-children-100317946","NCT03419260","Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children","Inclusion Criteria:\n\n1. Care in the Children's Hospital of Philadelphia Pediatric ICU.\n2. Clinically indicated continuous EEG monitoring.\n3. Age \\> 1 month to 18 years.\n\nExclusion Criteria:\n\n1. Admitted for Phase 2 (intracranial) EEG monitoring.\n2. Intensivist expects to discontinue technological support in the next two days given underlying medical or neurological problems.",{"count":375,"type":20},2500,"Electrographic seizures are common in critically ill patients leading to increased use of resource-intense continuous EEG monitoring for seizure identification and management. When identified, electrographic seizures are generally treated with anti-seizure medications, but there are very limited data available regarding optimal treatment in terms of the efficacy or safety of specific anti-seizure medications or overall management strategies.\n\nThis is a single-center prospective observational study. The investigators aim to: (1) track critically ill patients undergoing clinically indicated EEG monitoring and seizure management to identify risk factors for electrographic seizures, (2) create prediction models guiding EEG monitoring resources to the patients at highest risk for seizures, and (3) evaluate our current management strategy in terms of safety.",[378],"Seizures",[380,381,382],"seizures","status epilepticus","EEG monitoring","2026-06-24",{"date":362,"type":34},{"date":386,"type":34},"2017-03-13",{"date":388,"type":20},"2028-01-01",{"name":40,"class":41},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":16,"minAge":398,"maxAge":399,"enrollmentInfo":400,"targetDuration":4,"studyType":21,"phases":401,"briefSummary":402,"conditions":403,"keywords":410,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":422,"locationsCount":42},"100308878","phase-2-rifampin-in-cyp24a1-related-hypercalcemia-and-hypercalciuria-100308878","NCT03301038","Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria","Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene","RICHH","Inclusion Criteria:\n\n* Males or females age 6 months to 65 years.\n* at least one mutations of CYP24A1\n* Serum and\u002For urinary calcium above the normal reference range for age\n* Serum PTH concentration \\\u003C20 pg\u002Fml\n* Elevated or normal serum concentration of 1,25-dihydroxyvitamin D3.\n\nExclusion Criteria:\n\n* Parents\u002Fguardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.\n* Allergy to rifampin or related medications\n* Current therapies with medications that have significant drug-drug interactions with rifampin, defined as a medication considered to interact with CYP3A4 or CYP3A5 and either induce or inhibit expression or function of these P450 enzymes. By \"drug-drug\" interactions we are looking for medications that will affect metabolism or action of rifampin as exclusionary, not medications that will be affected by rifampin.\n* Pregnancy or breastfeeding\n* Laboratory abnormalities that indicate clinically significant hepatic, or renal disease:\n* Aspartate Aminotransferase (AST\u002FSGOT) \\> 2.0 times the upper limit of normal Alanine aminotransferase (ALT\u002FSGPT) \\> 2.0 times the upper limit of normal Total bilirubin \\> 2.0 times the upper limit of normal Creatinine \\> 2.0 times the upper limit of normal","6 Months","65 Years",{"count":220,"type":20},[105],"This study evaluates the efficacy of rifampin in the treatment of hypercalcemia and\u002For hypercalciuria in participants with at least one inactivating mutation of the CYP24A1 gene. Eligible subjects will receive rifampin for a total of 16 weeks during this study.",[404,405,406,407,408,409],"Idiopathic Infantile Hypercalcaemia - Severe Form","Genetic Disease","Hypercalcemia, Idiopathic, of Infancy","Hypercalciuric Hypercalcemia","Idiopathic Infantile Hypercalcemia - Mild Form","Hypercalciuria",[411,412,413,414],"hypercalcemia","nephrocalcinosis","CYP24A1","hypercalciuria","2026-06-18",{"date":417,"type":34},"2026-06-22",{"date":419,"type":34},"2018-07-25",{"date":421,"type":20},"2030-12",{"name":40,"class":41},{"id":424,"slug":425,"hasResults":12,"nctId":426,"briefTitle":427,"officialTitle":428,"acronym":4,"eligibilityCriteria":429,"healthyVolunteers":12,"sex":16,"minAge":284,"maxAge":241,"enrollmentInfo":430,"targetDuration":4,"studyType":21,"phases":432,"briefSummary":433,"conditions":434,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":42},"100594524","improving-mood-for-adolescents-through-teaming-with-end-users-in-routine-care-the-imatter-project-100594524","NCT07020572","Improving Mood for Adolescents Through Teaming With End-Users in Routine Care (The iMATTER Project)","The iMATTER Project: Preventing Adolescent Depression in Pediatric Primary Care","Inclusion Criteria:\n\nFor Adolescent Participants\n\n1. Adolescents ages 13 to 17 years.\n2. Adolescents must be English-speaking.\n3. Legal guardian permission (informed consent) and child consent\u002Fassent.\n4. A score of 5-10 on the Patient Health Questionnaire 9-Item: Modified for Teens (PHQ-9-M) at the primary care well-visit.\n5. Access to a phone, computer, or other electronic device that could be used for study activities\n\nFor Legal guardian Participants\n\n1. Legal guardian of an adolescents ages 13 to 17 years who scored 5-10 on the PHQ-9-M at the primary care well-visit.\n2. Consent to participate.\n3. English-speaking.\n4. Access to a phone, computer, and\u002For tablet to complete remote evaluations.\n\nExclusion Criteria:\n\nExclusion criteria will be determined based on electronic health record (EHR) review, eligibility screening questions, the baseline evaluation, and any other interactions with the family.\n\n1. Suicidal ideation or behaviors reported on the PHQ-9-M at their well-visit (score of 1 or higher on item 9 \"In the past week, have you had thoughts that you would be better off dead, or of hurting yourself in some way?\" and\u002For yes to either of the supplemental questions which ask, \"Has there been a time in the past month when you have had serious thoughts about ending your life?\" and \"Have you ever, in your whole life, tried to kill yourself or made a suicide attempt?\") based on medical record review. For the PHQ-9-M administered at baseline, adolescents who mark yes to the supplemental item about serious suicidal ideation in the past month (\"Has there been a time in the past month when you have had serious thoughts about ending your life?\") will be excluded.\n2. Major medical illness, significant behavioral problems or intellectual or developmental disabilities that may interfere with the completion of all study procedures.\n3. Youth may be excluded on a case-by-case basis if the EHR review, eligibility screener, baseline evaluation, or other interactions with the family suggests that the group program would not be appropriate.",{"count":431,"type":20},45,[23],"This pilot randomized controlled trial will examine the feasibility, acceptability and preliminary efficacy of an adolescent depression prevention program, Brief Interpersonal Psychotherapy-Adolescent Skills Training (B-IPT-AST), in primary care.",[435],"Depressive Symptoms","2026-06-12",{"date":438,"type":34},"2026-06-15",{"date":440,"type":34},"2025-03-20",{"date":442,"type":20},"2027-06",{"name":40,"class":41},{"id":445,"slug":446,"hasResults":12,"nctId":447,"briefTitle":448,"officialTitle":448,"acronym":449,"eligibilityCriteria":450,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":451,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":455,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":232},"100388454","autosomal-dominant-polycystic-kidney-disease-adpkd-study-100388454","NCT04338048","Autosomal Dominant Polycystic Kidney Disease (ADPKD) Study","ADPKD","Inclusion Criteria:\n\n* Demonstration of ADPKD by clinical information, imaging studies, biopsy, autopsy, or genetic testing.\n\nExclusion Criteria:\n\n* Patients with Autosomal Recessive Polycystic Kidney disease (ARPKD), urinary tract malformations or major congenital anomalies of other systems suggesting a diagnosis other than recessive hepato-renal fibrocystic diseases.",{"count":452,"type":20},300,"Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of renal failure. For several decades, ADPKD was regarded as an adult-onset disease. In the last decade, it has become more widely appreciated that the disease course begins in childhood. However, evidence-based guidelines on how to manage and approach children diagnosed with or at-risk for of ADPKD are lacking. Overall, there is insufficient data on the clinical course during childhood. The study intends to get more information on Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other hepato\u002Frenal fibrocystic diseases. Additionally, the study intends to expand web-based resources so anyone can learn about ADPKD or other hepato\u002Frenal fibrocystic diseases. Individuals diagnosed with the dominant form of a hepato\u002Frenal fibrocystic condition are invited to be in the study.",[449],{"date":438,"type":34},{"date":457,"type":34},"2019-10-10",{"date":459,"type":20},"2030-10-30",{"name":40,"class":41},{"id":462,"slug":463,"hasResults":12,"nctId":464,"briefTitle":465,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":469,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":471,"conditions":472,"keywords":483,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":492,"locationsCount":493},"100163551","arpkd-database-study-100163551","NCT01401998","ARPKD Database Study","Core A: The Hepato\u002FRenal Fibrocystic Diseases Translational Resource (ARPKD Database Study)","ARPKD","Inclusion Criteria:\n\n* Demonstration of hepato\u002Frenal fibrocystic disease by clinical information, imaging studies, biopsy, autopsy, or genetic testing.\n\nExclusion Criteria:\n\n* ADPKD Urinary tract malformations Major congenital anomalies of other systems",{"count":470,"type":20},200,"Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl syndrome, Meckel-Gruber syndrome, congenital hepatic fibrosis (CHF), Caroli syndrome (CS), polycystic liver disease, oro-facial-digital syndrome, nephronophithisis (NPHP), and glomerulocystic Kidney Disease).\n\nThe lack of enough routinely available resources for these diseases to be well diagnosed and treated, would be best resolved by coordinated case accrual and sharing of clinical data and bio-specimens (DNA and tissues) among participating institutions, thereby leading to the centralization and sharing of clinical and genetic information, as well as bio-materials, providing an important engine for more rapid research progress and community understanding through the creation of research networks.\n\nThis study aims to build a registry of a clinical database (medical health information), a mutational database (genetic information) and an educational resource about HRFD to eventually provide information about these diseases to families, physicians and genetic counselors via our existing HIPAA- approved study website.\n\nGoals for the Core A: The Hepato\u002FRenal Fibrocystic Diseases Translational Resource are:\n\n1. \\- Clinical Database:\n\n   • Expand our comprehensive Clinical Database to include information from all patients who meet the inclusion criteria for hepato\u002Frenal fibrocystic diseases.\n2. \\- Mutational Database:\n\n   * Test children with ARPKD and other hepato\u002Frenal fibrocystic disease to identify genetic mutations, establish a DNA bank for patients with hepato\u002Frenal fibrocystic diseases and develop a Mutational Database. This Database will be capable of linking clinical and mutational information via a unique identifier in a searchable format to facilitate genetic research (e.g. genotype-phenotype correlations, new disease gene studies, and modifier gene studies), translational studies, and clinical trials.\n\n     3- Tissue Resource:\n   * Much of the research that is performed on diseases of the kidney, including recessive genetic diseases, requires human tissue from both affected as well as non-affected (controls) individuals. In this Core Resource, we are establishing an independent tissue resource which would supply investigators throughout North America with samples of hepato\u002Frenal fibrocystic disease affected tissues for studies of these disorders.\n\n     4- Educational Resource:\n   * Expand our multi-media, web-based resource to provide a reliable up-to-date, and comprehensive informational resource for ARPKD and Hepato\u002FRenal Diseases families, their physicians, and genetic counselors.",[473,474,475,476,477,478,479,480,481,482],"Hepato\u002FRenal Fibrocystic Disease","Autosomal Recessive Polycystic Kidney Disease","Joubert Syndrome","Bardet Biedl Syndrome","Meckel-Gruber Syndrome","Congenital Hepatic Fibrosis","Caroli Syndrome","Oro-Facial-Digital Syndrome Type I","Nephronophthisis","Glomerulocystic Kidney Disease",[484,485,486,487],"cystic kidney disease","polycystic kidney disease","congenital hepatic fibrosis","genetic disease",{"date":438,"type":34},{"date":490,"type":4},"2011-06",{"date":421,"type":20},{"name":40,"class":41},6,{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":16,"minAge":352,"maxAge":501,"enrollmentInfo":502,"targetDuration":4,"studyType":21,"phases":504,"briefSummary":505,"conditions":506,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":514,"lastUpdatePostDateStruct":515,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":42},"100580644","phase-1-cd19-directed-chimeric-antigen-receptor-autologous-t-cells-cart19-for-lupus-100580644","NCT06839976","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus","CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Adolescents and Young Adults With Systemic Lupus Erythematosus (SLE)","Inclusion Criteria:\n\n1. Signed informed consent form must be obtained prior to any study procedure. Labs or other procedures obtained during routine clinical care may be used for eligibility if obtained within the protocol required window.\n2. Patient age must be 12-29 years, inclusive, at time of enrollment.\n3. Meeting ACR\u002FEULAR Classification Criteria for SLE\n4. ANA positive \\> 1:80 and\u002For double-stranded DNA (dsDNA) positive\n5. Active (refractory) disease, defined as follows:\n\n   a. Lupus nephritis subjects must meet both the following criteria: i. ISN\u002FRPS active nephritis Class III\u002FIV +\u002F- V lupus nephritis diagnosed by biopsy within past 12 months.\n\nii. Persistent and clinically significant: ≥2 measurements with urine protein with either of the following:\n\n1. \\> 1mg\u002Fmg creatinine\n2. \\> 0.5 mg\u002Fmg creatinine associated with renal dysfunction or low albumin.\n3. \\> 0.5 mg\u002Fmg creatinine in a patient with rising proteinuria after prior complete renal response b. Non-renal SLE subjects must meet either of the following criteria: i. SLEDAI-2K ≥ 8 and clinical SLEDAI-2K ≥ 6 ii. Inability to decrease prednisone ≤7.5mg\u002Fday or 0.15mg\u002Fkg\u002Fday, whichever is lower, due to active disease.\n\n6\\. Patients must have had at least 3 months of cumulative conventional therapy defined as:\n\n1. Conventional induction immunosuppressive agent(s) (e.g., mycophenolate mofetil, cyclophosphamide), and\n2. At least one additional therapy:\n\ni. B-cell directed biologic therapy (e.g., rituximab, belimumab, ofatumumab, obinutuzumab) ii. Calcineurin inhibitor (e.g., tacrolimus, cyclosporine, voclosporin) iii. Other immunosuppressive medication for SLE (e.g., anifrolumab, abatacept, JAK inhibitor) 7. Adequate organ function status\n\n1. Renal: eGFR must be ≥30 and subject cannot be receiving dialysis.\n2. Hepatic: Transaminases \\\u003C 5x upper limit of normal and serum conjugated (Direct) bilirubin \\\u003C1.5x upper limit of normal unless attributable to SLE. If attributable to autoimmune disease, Child-Pugh score must be class A or class B. Child-Pugh score cannot be class C.\n3. Cardiac: Shortening fraction \\> 28%, left ventricular ejection fraction \\>45%, and no evidence of severe pulmonary hypertension\n4. Pulmonary: Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and \\\u003CGrade 3 hypoxia; DLCO ≥40% (corrected for anemia and\u002For VA volume if necessary) if PFTs are clinically appropriate as determined by the treating investigator.\n\n   8\\. Subjects of reproductive potential must agree to use acceptable birth control methods.\n\nExclusion Criteria:\n\n1. Active, untreated infections\n2. HIV infection\n3. Active Hepatitis B\n\n   a. Patients must have a negative hepatitis B surface antigen to be enrolled on this study.\n4. Active Hepatitis C\n5. Patients with severe neuropsychiatric lupus or neurologic manifestations of SLE (e.g. stroke, seizure, psychosis, demyelinating syndromes, organic brain syndrome, or lupus related headaches)\n6. Monogenic lupus (known)\n7. Previous autologous or allogenic stem cell transplant\n8. Previous kidney transplant\n9. History of seizure disorder\n10. Patients who are on anti-epileptic therapy\n11. Participation in a clinical trial in which the patient receives an investigational drug within a time period equal or less than 5.5 half-lives of the investigational agent prior to study enrollment.\n12. Subjects who are unwilling or unable to discontinue immunosuppressive medications at the times of CART19 infusion will be excluded from the trial\n13. Any comorbidity that in the opinion of the investigators would jeopardize the ability of the subject to tolerate therapy.\n14. Pregnant patients. All participants of childbearing potential must have negative pregnancy test.\n15. Lactating participants who want to continue breastfeeding.\n16. Patients who are unwilling to consent to LTFU","29 Years",{"count":503,"type":20},24,[54,105],"This is a single-center, single-arm, open-label phase 1\u002F2 study of CART19 in children and young adults with refractory Systemic lupus erythematosus (SLE), including both patients diagnosed with lupus nephritis (LN) and patients with non-renal Systemic lupus erythematosus (SLE).\n\nPhase 1 will evaluate the safety of CART19 in 6-12 patients with Systemic lupus erythematosus (SLE). There is no planned dose escalation, but a dose de-escalation will be made based on the incidence of Dose Limiting Toxicities. Phase 2 will evaluate the efficacy and further evaluate the safety of CART19 in this population.",[507,508,509,510,511,512,513],"SLE","Systemic Lupus Erythematosus (SLE)","CAR T Cell","CART19","Cell Therapy","Lupus","Lupus Nephritis (LN)","2026-06-11",{"date":438,"type":34},{"date":517,"type":34},"2025-05-06",{"date":519,"type":20},"2030-02-28",{"name":40,"class":41},{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":4,"eligibilityCriteria":527,"healthyVolunteers":12,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":528,"targetDuration":530,"studyType":79,"phases":4,"briefSummary":531,"conditions":532,"keywords":534,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":541,"lastUpdatePostDateStruct":542,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":42},"100509198","synovial-sarcoma-registry--biospecimen-repository-100509198","NCT05910307","Synovial Sarcoma Registry \u002F Biospecimen Repository","Synovial Sarcoma Registry and Biospecimen Repository","Inclusion Criteria:\n\n1. Males or females of any age\n2. Reported diagnosis of synovial sarcoma\n3. Informed consent from subject (aged ≥18 years) or parent\u002Fguardian\n\nExclusion Criteria:\n\n1. Individuals with sarcomas that do not fit the definition of those considered for this registry\n2. Individuals who are unwilling to participate\n3. Individuals who are unwilling or unable to provide written consent",{"count":529,"type":20},1000,"10 Years","The purpose of this study is to collect and store data and samples for future research to attempt to improve outcomes for patients with synovial sarcoma. The future research will involve various types of genetic testing.\n\nParticipants will be asked to allow access to medical records and leftover tumor tissue and may be asked to give a blood or saliva sample. Participants will also be asked to completed questionnaires about their medical history and may be contacted every 6 to 12 months for updates for up to 10 years.",[533],"Synovial Sarcoma",[535,536,537,538,539,540],"registry","biorepository","sarcoma","oncology","cancer","rare tumor","2026-06-05",{"date":543,"type":34},"2026-06-09",{"date":545,"type":34},"2023-06-12",{"date":547,"type":20},"2033-06",{"name":40,"class":41},{"id":550,"slug":551,"hasResults":12,"nctId":552,"briefTitle":553,"officialTitle":554,"acronym":555,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":16,"minAge":557,"maxAge":131,"enrollmentInfo":558,"targetDuration":4,"studyType":21,"phases":559,"briefSummary":561,"conditions":562,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":564,"lastUpdatePostDateStruct":565,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":42},"100385002","early-phase-1-treatment-of-bk-virus-infection-with-ctl-cells-in-immunocompromised-transplant-patients-100385002","NCT04293042","Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients","A Pilot Study in the Treatment of BK Virus Infection With Cytotoxic T Cells in Immunocompromised Transplant Patients","BK-CTLs","Inclusion Criteria:\n\nPatient Eligibility\n\n* Patients with symptoms of cystitis and elevated BK virus DNA by screening PCR as above (section 4) post allogeneic HSCT, post chemotherapy\n\n  1. Symptoms of cystitis may include: hematuria (microscopic or gross), pain with urination, frequency, bladder spasms.\n  2. Patient may be otherwise treated for cystitis as per local institutional standards. Such treatments may include hydration, antiviral medications, or surgical intervention as deemed appropriate by treating physician.\n* Consent: Written informed consent given (by patient or legal representative) prior to any study-related procedures.\n* Performance Status \\> 30% (Lansky \\\u003C 16 yrs and Karnofsky \\> 16 yrs)\n* Age: 0.1 to 25 years\n* Females of childbearing potential with a negative urine pregnancy test.\n\nDonor Eligibility\n\n* Related donor available with a T-cell response to the BK-virus MACS® PepTivator® antigen(s).\n\n  1. Original allogeneic donor if available, IgG positive for BKV or confirmatory testing to respond to BKV MACS Peptivator®.\n  2. Third Party Allogeneic Donor: If original donor is not available or does not have a T-cell response: third party allogeneic donor (family donor \\> 1 HLA A, B, DR match to recipient) with a T-cell response to the BK MACS® PepTivator.\n\n     AND\n* Allogeneic donor disease screening is complete similar to hematopoietic stem cell donors (Appendix 1).\n\nAND\n\n• Obtained informed consents by donor or donor legally authorized representative prior to donor collection.\n\nExclusion Criteria:\n\nPatient exclusion criteria:\n\nA patient meeting any of the following criteria is not eligible for the present study:\n\n* Patient with acute GVHD \\> grade 2 or extensive chronic GVHD at the time of BK Virus CTL infusion\n* Patient receiving steroids (\\>0.5 mg\u002Fkg prednisone equivalent) at the time of BK Virus CTL infusion or within 3 days of planned infusion.\n* Thymoglobulin (ATG), campath or T cell immunosuppressive monoclonal antibodies within 30 days\n* Patient with poor performance status determined by Karnofsky (patients \\>16 years) or Lansky (patients ≤16 years) score ≤30%\n* Concomitant enrollment in another experimental clinical trial investigating the treatment of refractory BK virus infection.\n* Any medical condition which could compromise participation in the study according to the investigator's assessment\n* Known HIV infection\n* Female patient of childbearing age who is pregnant or breast-feeding or not willing to use an effective method of birth control during study treatment.\n* Known hypersensitivity to iron dextran\n* Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n* Known human anti-mouse antibodies","5 Weeks",{"count":52,"type":20},[560],"EARLY_PHASE1","This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.",[563],"BK Polyomavirus","2026-06-04",{"date":541,"type":34},{"date":567,"type":34},"2019-10-07",{"date":569,"type":20},"2029-01-30",{"name":40,"class":41},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":575,"acronym":4,"eligibilityCriteria":576,"healthyVolunteers":157,"sex":16,"minAge":158,"maxAge":352,"enrollmentInfo":577,"targetDuration":4,"studyType":21,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":592,"locationsCount":42},"100493299","optimizing-a-mobile-health-platform-for-sleep-promotion-and-obesity-prevention-in-children-100493299","NCT05703347","Optimizing a Mobile Health Platform for Sleep Promotion and Obesity Prevention in Children","Inclusion Criteria:\n\n1. Aged 8-12 years olds.\n2. Insufficient sleep duration (\\\u003C8.5 hours per night).\n3. Body mass index (BMI) between the 50th and 95th percentile for age and sex.\n4. One child per family.\n\nExclusion Criteria:\n\n1. Diagnosed with a chronic disease.\n2. Diagnosed with a behavioral health problem.\n3. Diagnosed with a condition that can impact sleep or growth.\n4. Diagnosed with a condition affecting physical growth and maturation or dietary intake.\n5. Children with a history of cancer, kidney, GI, musculoskeletal, or sleep disorders.\n6. Children who will transition to high-school during the study.\n7. Children using steroids\u002Fhormones.\n8. Children regularly taking medications related to exclusionary medical conditions or that impact sleep.\n9. Children with a history of significant behavioral health concerns.\n10. Parent reported PROMIS Parent Proxy Sleep Disturbance - Short Form 8a raw score of ≥28.",{"count":578,"type":20},5000,[23],"The overall objective of this application is to develop a mobile health platform for the pediatric care setting to promote longer sleep duration for childhood obesity prevention.",[290,582],"Obesity",[584,585],"insufficient sleep","obesity","2026-05-22",{"date":588,"type":34},"2026-05-27",{"date":590,"type":34},"2023-09-21",{"date":442,"type":20},{"name":40,"class":41},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":16,"minAge":284,"maxAge":17,"enrollmentInfo":600,"targetDuration":4,"studyType":21,"phases":602,"briefSummary":603,"conditions":604,"keywords":609,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":614,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":42},"100496221","facilitating-access-to-specialty-treatment-100496221","NCT05741411","Facilitating Access to Specialty Treatment","Utilizing Mobile Health to Expedite Access to Specialty Care for Youth Presenting to the Emergency Department With Concussion at Highest Risk of Developing Persisting Symptoms","Inclusion Criteria for concussed subjects:\n\n* Males and females age 13 - 18\n* Present to the Children's Hospital of Philadelphia (CHOP) Emergency Department (ED) within 72 hours of head injury\n* Meet criteria for concussion as defined by the most recent International Consensus Statement on Concussion\n* Own a smartphone\n* Meet criteria for moderate-to-high risk for Persistent Post-Concussion Symptoms according to 5P rule (score \\>3\u002F12)\n\nExclusion Criteria for concussed subjects:\n\n* Glasgow Coma Scale score \\\u003C13\n* Lower extremity trauma\n* A prior concussion within 1 month\n* Non-English speaking\n* Admission to the hospital at the initial head injury visit\n* Previously enrolled in the study\n* Inability to complete study procedures.\n\nInclusion Criteria for parents:\n\n* Child meets the study eligibility criteria\n\nExclusion Criteria for parents:\n\n* Non-English speaking\n\nInclusion Criteria for providers:\n\n* ED or specialty provider caring for at least one patient via the mobile Health (mHealth)-facilitated care handoff strategy\n\nExclusion Criteria for providers:\n\n* Non-English speaking",{"count":601,"type":20},210,[23],"The goal of this hybrid implementation-effectiveness study is to evaluate the effectiveness (hastened recovery times) and feasibility (fidelity in connecting to concussion specialty care) of a novel mobile health intervention, designed to reduce disparities in access to specialty care through the use of remote patient monitoring (RPM) to facilitate care hand-off from the emergency department (ED) to concussion specialty care. Participants will report their symptoms and activity once daily through RPM chat technology that is linked to their electronic health record and prompts referral to specialty care.",[605,606,607,608],"Mild Traumatic Brain Injury","Concussion, Mild","Concussion, Severe","Concussion, Intermediate",[610,611,612,613],"mobile health","emergency department","persistent post-concussion symptoms","remote patient monitoring","2026-05-20",{"date":586,"type":34},{"date":617,"type":34},"2024-03-11",{"date":619,"type":20},"2027-08-01",{"name":40,"class":41},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":626,"acronym":627,"eligibilityCriteria":628,"healthyVolunteers":12,"sex":16,"minAge":75,"maxAge":241,"enrollmentInfo":629,"targetDuration":4,"studyType":21,"phases":630,"briefSummary":631,"conditions":632,"keywords":634,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":639,"lastUpdatePostDateStruct":640,"startDateStruct":642,"completionDateStruct":644,"leadSponsor":645,"locationsCount":42},"100599410","phase-1-vancomycin-and-acute-kidney-injury-in-sepsis-treatment---intervention-100599410","NCT07084129","Vancomycin and Acute Kidney Injury in Sepsis Treatment - Intervention","Vancomycin and Acute Kidney Injury in Sepsis Treatment - Pharmacologic Modeling Intervention","VAST-i","Inclusion Criteria:\n\n1. Age \\>1 month and \\\u003C18 years\n2. Weight \\>5kg and \\\u003C50kg\n3. Vancomycin intended duration of therapy ≥48 hours\n4. Admitted to intensive care unit with suspected or confirmed sepsis\n5. Either sepsis-induced respiratory (invasive mechanical ventilation) or cardiovascular (vasoactive infusion) dysfunction as part of sepsis-associated organ dysfunction (these organ dysfunctions may be improving or resolved at the time of enrollment)\n\nExclusion Criteria:\n\n1. Serum creatinine elevated and meets criteria for trough-based dosing by local Clinical Pharmacy\n2. Methicillin resistant Staph aureus minimum inhibitory concentration (MIC)\\>1\n3. Central nervous system infection\n4. Extracorporeal support (extracorporeal membrane oxygenation, continuous renal replacement therapy)\n5. Pregnancy\n6. Patients on chronic dialysis therapy\n7. Patients with known history of delayed vancomycin clearance based on local pharmacy records",{"count":52,"type":20},[54],"The goal of this clinical trial is to determine if vancomycin dosing in children with sepsis can be improved by using updated, personalized dosing models that account for new markers of an individual's kidney function. Vancomycin is prescribed based on the known information of how the body breaks this medicine down. Vancomycin may not be effective if blood levels of the medicine are too low. Vancomycin has potential side effects, including the possibility of injury to the kidney. These side effects usually happen when blood levels of vancomycin are too high. There are guidelines for the range of vancomycin blood levels doctors should target to treat an infection and lower the risk of side effects. Children with sepsis may metabolize vancomycin at different rates, faster or slower, than children who do not have sepsis. For these reasons, the current dosing strategy may lead to a higher risk of kidney injury or a risk of not adequately treating an infection in children with sepsis. The investigators' goal is to use new vancomycin dosing equations to improve the ability to select the right dose of vancomycin. The main questions this trial aims to answer are:\n\n1. Is it feasible to use personalized models of vancomycin dosing in children with sepsis?\n2. Will personalized models of vancomycin dosing achieve vancomycin blood levels in acceptable ranges?",[633],"Sepsis",[635,636,637,638],"sepsis","vancomycin","biomarker","pharmacokinetics","2026-05-15",{"date":641,"type":34},"2026-05-18",{"date":643,"type":34},"2026-04-15",{"date":255,"type":20},{"name":40,"class":41},""]